TLDR Crinetics Pharmaceuticals doubled after Vertex Pharmaceuticals agreed to buy it for $10 billion in cash Rivian dropped 9% after announcing a 75 million shareTLDR Crinetics Pharmaceuticals doubled after Vertex Pharmaceuticals agreed to buy it for $10 billion in cash Rivian dropped 9% after announcing a 75 million share

Today’s Market Movers: Crinetics Doubles on $10B Deal While Rivian and Micron Stocks Sink

2026/07/07 19:22
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Crinetics Pharmaceuticals doubled after Vertex Pharmaceuticals agreed to buy it for $10 billion in cash
  • Rivian dropped 9% after announcing a 75 million share sale to repay a government loan
  • Micron fell 5% on fears of a memory chip supply glut from Samsung and SK Hynix spending
  • Fiserv jumped up to 8% on reports of talks to sell its STAR Network to major banks
  • AI and chip stocks fell broadly in premarket, with Intel down 4.4% and Samsung down nearly 7%

Artificial intelligence and chip stocks fell sharply in premarket trading on Tuesday, July 7. The losses pointed to a quick end to Monday’s rebound.

Samsung Electronics started the slide overnight. The South Korean chipmaker forecast a major profit jump, but investors sold off shares anyway, sending the stock down nearly 7%.

That weakness spread to U.S. markets. Intel fell 4.4% and Micron Technology dropped 5.8% before the opening bell.


INTC Stock Card
Intel Corp., INTC

Advanced Micro Devices, Corning, Marvell Technology, and Super Micro Computer were also in the red. All have ties to the AI sector.

Nasdaq futures fell, while the Dow held steadier. Investors appear to be taking a closer look at AI stock valuations ahead of economic data due later in the week.

Crinetics Doubles on Vertex Buyout Deal

Crinetics Pharmaceuticals was the biggest gainer of the day by far. Shares jumped 100%, reaching $83.66 in premarket trading.

Vertex Pharmaceuticals agreed to buy Crinetics for $85 per share in an all-cash deal. The total equity value is around $10 billion.

The deal is expected to close in the third quarter of 2026. Vertex said the acquisition will immediately add revenue through the launch of Palsonify, a treatment for acromegaly.

Vertex also pointed to pipeline drug atumelnant as a potential multi-billion-dollar opportunity. The combined assets are expected to generate more than $5 billion in peak annual revenue.

Fiserv also rose, gaining around 6% to 8%. The Wall Street Journal reported that JPMorgan Chase, Bank of America, Wells Fargo, and PNC Financial Services held talks to buy Fiserv’s STAR Network payments business.

Rivian Falls on Share Sale, Micron Drops on Supply Fears

Rivian Automotive was among the biggest losers. Shares fell around 9% after the company said it would sell 75 million Class A shares.

The proceeds will go toward general corporate purposes, including repaying a $4.5 billion loan from the U.S. Department of Energy.

Rivian did report stronger-than-expected revenue guidance for the second quarter. The company estimated $1.55 billion to $1.65 billion in revenue, above the $1.44 billion analyst consensus.

Micron fell around 5%. Investors worried that aggressive spending by Samsung and SK Hynix could lead to a memory chip supply glut and push down prices.

SpaceX slipped 1.3% in premarket. The company was set to join the Nasdaq 100 before the market opened Tuesday.

Stock futures were mixed overall. The day’s moves reflected a market weighing a strong biotech deal against pressure in chips and electric vehicles.

The post Today’s Market Movers: Crinetics Doubles on $10B Deal While Rivian and Micron Stocks Sink appeared first on CoinCentral.

Market Opportunity
ShareX Logo
ShareX Price(SHARE)
$0.2001
$0.2001$0.2001
+0.50%
USD
ShareX (SHARE) Live Price Chart

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

$5M in SPCX Positions for Free

$5M in SPCX Positions for Free$5M in SPCX Positions for Free

0 fees, 100x leverage, daily prizes, 7K+ stocks/ETFs